CN107602698A - 新的单克隆抗体以及d二聚体的免疫学测定方法 - Google Patents
新的单克隆抗体以及d二聚体的免疫学测定方法 Download PDFInfo
- Publication number
- CN107602698A CN107602698A CN201710866756.8A CN201710866756A CN107602698A CN 107602698 A CN107602698 A CN 107602698A CN 201710866756 A CN201710866756 A CN 201710866756A CN 107602698 A CN107602698 A CN 107602698A
- Authority
- CN
- China
- Prior art keywords
- fragment
- antibody
- dimer
- reagent
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003154 D dimer Substances 0.000 title claims abstract description 122
- 238000000034 method Methods 0.000 title description 45
- 238000010324 immunological assay Methods 0.000 title description 3
- 239000012634 fragment Substances 0.000 claims abstract description 176
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 60
- 238000006243 chemical reaction Methods 0.000 claims abstract description 42
- 239000000178 monomer Substances 0.000 claims abstract description 42
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 32
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 32
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 31
- 108010073385 Fibrin Proteins 0.000 claims abstract description 28
- 102000009123 Fibrin Human genes 0.000 claims abstract description 28
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229950003499 fibrin Drugs 0.000 claims abstract description 27
- 238000003556 assay Methods 0.000 claims abstract description 17
- 108010088842 Fibrinolysin Proteins 0.000 claims abstract description 16
- 229940001501 fibrinolysin Drugs 0.000 claims abstract description 16
- 238000010494 dissociation reaction Methods 0.000 claims abstract description 10
- 230000005593 dissociations Effects 0.000 claims abstract description 10
- 108010069898 fibrinogen fragment X Proteins 0.000 claims abstract description 10
- 206010013457 Dissociation Diseases 0.000 claims abstract description 8
- 208000018459 dissociative disease Diseases 0.000 claims abstract description 8
- 210000004408 hybridoma Anatomy 0.000 claims description 15
- 230000001900 immune effect Effects 0.000 claims description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 239000000539 dimer Substances 0.000 claims description 6
- 230000000087 stabilizing effect Effects 0.000 abstract description 3
- 239000004816 latex Substances 0.000 description 36
- 229920000126 latex Polymers 0.000 description 36
- 239000000243 solution Substances 0.000 description 35
- 230000004520 agglutination Effects 0.000 description 18
- 230000009257 reactivity Effects 0.000 description 18
- 229920000642 polymer Polymers 0.000 description 16
- 239000002245 particle Substances 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 239000000872 buffer Substances 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000007910 cell fusion Effects 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 229940106780 human fibrinogen Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 230000004523 agglutinating effect Effects 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000003527 fibrinolytic agent Substances 0.000 description 3
- 230000003480 fibrinolytic effect Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 2
- 239000006173 Good's buffer Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- -1 ester acrylate Chemical class 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229920000620 organic polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PHXKQKZYWQUGLW-UHFFFAOYSA-N 1h-pyrrole;pyrrolidin-2-one Chemical compound C=1C=CNC=1.O=C1CCCN1 PHXKQKZYWQUGLW-UHFFFAOYSA-N 0.000 description 1
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- 239000007988 ADA buffer Substances 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 239000007992 BES buffer Substances 0.000 description 1
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000007996 HEPPS buffer Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000013098 chemical test method Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- HHLJUSLZGFYWKW-UHFFFAOYSA-N triethanolamine hydrochloride Chemical compound Cl.OCCN(CCO)CCO HHLJUSLZGFYWKW-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (5)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010084863 | 2010-04-01 | ||
JP2010-084863 | 2010-04-01 | ||
CN2011800179105A CN102822338A (zh) | 2010-04-01 | 2011-03-31 | 新的单克隆抗体以及d二聚体的免疫学测定方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011800179105A Division CN102822338A (zh) | 2010-04-01 | 2011-03-31 | 新的单克隆抗体以及d二聚体的免疫学测定方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107602698A true CN107602698A (zh) | 2018-01-19 |
Family
ID=44762813
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710866756.8A Pending CN107602698A (zh) | 2010-04-01 | 2011-03-31 | 新的单克隆抗体以及d二聚体的免疫学测定方法 |
CN2011800179105A Pending CN102822338A (zh) | 2010-04-01 | 2011-03-31 | 新的单克隆抗体以及d二聚体的免疫学测定方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011800179105A Pending CN102822338A (zh) | 2010-04-01 | 2011-03-31 | 新的单克隆抗体以及d二聚体的免疫学测定方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9206250B2 (zh) |
EP (1) | EP2554673B1 (zh) |
JP (1) | JP5860394B2 (zh) |
KR (1) | KR101877457B1 (zh) |
CN (2) | CN107602698A (zh) |
BR (1) | BR112012025082A8 (zh) |
ES (1) | ES2655099T3 (zh) |
HK (1) | HK1248249A1 (zh) |
WO (1) | WO2011125875A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110028582A (zh) * | 2019-04-29 | 2019-07-19 | 江苏众红生物工程创药研究院有限公司 | 抗人d-二聚体抗体及其应用 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5903381B2 (ja) * | 2010-07-30 | 2016-04-13 | シスメックス株式会社 | 抗fdpモノクローナル抗体、それを用いたfdp測定用試薬及び試薬キット、並びにfdp測定方法 |
WO2012014996A1 (ja) * | 2010-07-30 | 2012-02-02 | シスメックス株式会社 | Fdp測定用試薬及び試薬キット、並びに測定方法 |
CN103033629B (zh) * | 2012-12-12 | 2015-02-25 | 元升生物科技(上海)有限公司 | 一种脂蛋白磷脂酶a2的测定试剂及试剂的制备方法 |
CN103468644B (zh) * | 2013-09-26 | 2016-01-20 | 重庆探生科技有限公司 | 产生抗人d-二聚体的单克隆抗体的杂交瘤细胞株及制备方法和应用 |
CN108700570B (zh) * | 2016-02-22 | 2022-03-11 | 美迪恩斯生命科技株式会社 | 交联纤维蛋白分解产物的测定试剂及测定方法 |
JP6667380B2 (ja) * | 2016-06-17 | 2020-03-18 | シスメックス株式会社 | 血液分析のための方法、血液分析装置、コンピュータプログラム、キャリブレータセット、及びキャリブレータセットの作製方法 |
WO2021165914A1 (en) * | 2020-02-20 | 2021-08-26 | Grifols Diagnostic Solutions Inc. | Anti d-dimer recombinant antibodies, methods and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0842949A1 (en) * | 1996-05-15 | 1998-05-20 | Iatron Laboratories, Inc. | NOVEL MONOCLONAL ANTIBODY AND METHOD OF IMMUNOLOGICAL ANALYSIS OF e-D DIMER AND e-DD/E COMPLEX |
CN101166977A (zh) * | 2005-04-28 | 2008-04-23 | 株式会社三菱化学药得论 | 稳定化纤维蛋白的纤维蛋白溶酶分解物的免疫学分析方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU572125B2 (en) | 1983-03-17 | 1988-05-05 | Mabco Limited | Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses |
JPS6379900A (ja) | 1986-09-22 | 1988-04-09 | Yatoron:Kk | モノクロ−ナル抗体と検出方法 |
JP3857468B2 (ja) | 1999-07-12 | 2006-12-13 | 株式会社三菱化学ヤトロン | Dダイマー及びdd/e複合体の免疫学的分析方法及び分析用キット |
WO2003039234A2 (en) * | 2001-11-06 | 2003-05-15 | David Pickar | Pharmacogenomics-based system for clinical applications |
JP4448754B2 (ja) | 2004-09-30 | 2010-04-14 | シスメックス株式会社 | Dダイマー測定用試薬およびこれに用いるモノクローナル抗体 |
JP4589756B2 (ja) | 2005-02-25 | 2010-12-01 | シスメックス株式会社 | Dダイマー測定用キット |
EP1917532A4 (en) * | 2005-07-29 | 2009-10-21 | Biobud Co Ltd | ANTI-D-DIMER MONOCLONAL ANTIBODY AS A DIAGNOSTIC AGENT FOR DETECTING D-DIMER, RETICULATED FIBRIN AND ITS DERIVATIVES CONTAINING D-DIMERS |
ES2621923T3 (es) * | 2007-09-11 | 2017-07-05 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarcador para medir la eficacia de un fármaco en enfermedad enteropática |
-
2011
- 2011-03-31 WO PCT/JP2011/058286 patent/WO2011125875A1/ja active Application Filing
- 2011-03-31 EP EP11765775.9A patent/EP2554673B1/en active Active
- 2011-03-31 US US13/637,973 patent/US9206250B2/en active Active
- 2011-03-31 JP JP2012509590A patent/JP5860394B2/ja active Active
- 2011-03-31 KR KR1020127028395A patent/KR101877457B1/ko active IP Right Grant
- 2011-03-31 BR BR112012025082A patent/BR112012025082A8/pt not_active Application Discontinuation
- 2011-03-31 CN CN201710866756.8A patent/CN107602698A/zh active Pending
- 2011-03-31 ES ES11765775.9T patent/ES2655099T3/es active Active
- 2011-03-31 CN CN2011800179105A patent/CN102822338A/zh active Pending
-
2018
- 2018-06-14 HK HK18107694.4A patent/HK1248249A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0842949A1 (en) * | 1996-05-15 | 1998-05-20 | Iatron Laboratories, Inc. | NOVEL MONOCLONAL ANTIBODY AND METHOD OF IMMUNOLOGICAL ANALYSIS OF e-D DIMER AND e-DD/E COMPLEX |
CN101166977A (zh) * | 2005-04-28 | 2008-04-23 | 株式会社三菱化学药得论 | 稳定化纤维蛋白的纤维蛋白溶酶分解物的免疫学分析方法 |
Non-Patent Citations (3)
Title |
---|
STEPHANIE A. OLEXA 等: "Primary Soluble Plasmic Degradation of Human Cross-linked Fibrin. Isolation and Stoichiometry of the (DD)E Complex", 《BIOCHEMISTRY》 * |
WAYNE M.YOKOYAMA 等: "Production of Monoclonal Antibodies", 《CURRENT PROTOCOLS IN IMMUNOLOGY》 * |
董怀平 等: "D-二聚体的研究进展", 《国际检验医学杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110028582A (zh) * | 2019-04-29 | 2019-07-19 | 江苏众红生物工程创药研究院有限公司 | 抗人d-二聚体抗体及其应用 |
CN110028582B (zh) * | 2019-04-29 | 2022-03-25 | 江苏众红生物工程创药研究院有限公司 | 抗人d-二聚体抗体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
EP2554673A4 (en) | 2014-05-21 |
BR112012025082A2 (pt) | 2015-09-22 |
US20130011869A1 (en) | 2013-01-10 |
JP5860394B2 (ja) | 2016-02-16 |
HK1248249A1 (zh) | 2018-10-12 |
KR101877457B1 (ko) | 2018-07-11 |
EP2554673B1 (en) | 2017-10-25 |
JPWO2011125875A1 (ja) | 2013-07-11 |
US9206250B2 (en) | 2015-12-08 |
BR112012025082A8 (pt) | 2017-10-10 |
CN102822338A (zh) | 2012-12-12 |
WO2011125875A1 (ja) | 2011-10-13 |
KR20130032869A (ko) | 2013-04-02 |
ES2655099T3 (es) | 2018-02-16 |
EP2554673A1 (en) | 2013-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107602698A (zh) | 新的单克隆抗体以及d二聚体的免疫学测定方法 | |
EP2322562B1 (en) | Monoclonal antibody, and immunoassay using same | |
US9541564B2 (en) | Reagent for assaying D-dimer and kit of reagent for assaying D-dimer | |
CN108139392A (zh) | Pivka-ii的测定方法及pivka-ii免疫测定试剂或试剂盒的制造方法 | |
JPWO2010064435A1 (ja) | ヒト体液中のシスタチンc測定方法 | |
KR100202773B1 (ko) | 프로트롬빈 활성화 펩타이드 및 그것의 분해생성물에 대한 모노클론 항체 및 면역 분석법 | |
KR102100152B1 (ko) | Pivka-ⅱ 측정 방법, 측정 시약 및 측정 키트 | |
WO1995012617A1 (fr) | Hybridome d'anticorps anti-fibrine soluble humaine, et procede d'immunodosage | |
US9322825B2 (en) | Modified anti-heparin/PF4 complex antibody and HIT antibody standard | |
KR20170132310A (ko) | 트롬빈 안티트롬빈 복합체의 측정 시약 및 측정 방법 | |
JPH0746104B2 (ja) | Fdpの測定法 | |
JP3857468B2 (ja) | Dダイマー及びdd/e複合体の免疫学的分析方法及び分析用キット | |
JP3472138B2 (ja) | モノクローナル抗体及びfdpの測定方法 | |
EP0315447A2 (en) | Method of immunological measurement of human protein S and reagent and kit therefor | |
JP2001354700A (ja) | モノクロ−ナル抗体及びヒトフィブリン分解産物の測定方法 | |
JP5891491B2 (ja) | 試料中の総プロテインsタンパク質量の測定試薬及び測定方法 | |
CN107002065A (zh) | 对TRACP‑5b(酒石酸抵抗性酸性磷酸酶5b)具有特异性的蛋白定量法 | |
JP3142786B2 (ja) | 動脈硬化症の測定用キット及びこれに用いる抗体 | |
JPS6379900A (ja) | モノクロ−ナル抗体と検出方法 | |
JP3973169B2 (ja) | トランスフェリン−トランスフェリンレセプター・コンプレックス測定試薬および測定方法 | |
JP2005321411A (ja) | トランスフェリン−トランスフェリンレセプター・コンプレックス測定試薬および測定方法 | |
JPH07196698A (ja) | 抗ヒトホスホリパーゼエイツー活性化蛋白質抗体とこの抗体を産生するハイブリドーマ、並びにこの抗体を用いたヒトホスホリパーゼエイツー活性化蛋白質の測定用試薬及び測定方法 | |
JPH06113880A (ja) | モノクローナル抗体及びこれを用いたリポプロティンスモールaの測定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1248249 Country of ref document: HK |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240418 Address after: Ehime Prefecture, Japan Applicant after: Pu Heji Country or region after: Japan Address before: Tokyo, Japan Applicant before: LSI MEDIENCE Corp. Country or region before: Japan |